Ekaterina S. Klyachina

Ekaterina S. Klyachina

Auto-generated profile, based on publicly available information

Ekaterina S. Klyachina

Ural State Medical University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2024 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
VNVeronika Naumova
Veronika Naumova
EBE. K. Beltyukov
E. K. Beltyukov
OKO. P. Kovtun
O. P. Kovtun
OSO. G. Smolenskaya
O. G. Smolenskaya
GBG. A. Bykova
G. A. Bykova
EKE. S. Klyachina
E. S. Klyachina
Introduction. Severe asthma targeted therapy effectiveness depends on precise targeting of the selected drug to the key link in pathogenesis. Therefore, severe asthma phenotyping in real clinical practice is relevant.Aim. To determine main clinical and allergological characteristics of patients with severe asthma and to establish important phenotyping signs determined choice of a targeted drug for severe asthma treatment.Materials and methods. The prospective and retrospective study involved patients (n = 198) of the Sverdlovsk region registry receiving targeted therapy of severe asthma. Considering clinical and allergological picture, allergic, non-allergic eosinophilic and mixed severe asthma phenotypes were identified. Clinical and laboratory characteristics of phenotypes were described. A phenotyping algorithm was developed.Results. In the register of patients (n = 198) with severe asthma, non-allergic eosinophilic asthma was 46.5%, allergic – 34.8%, mixed – 18.7%. Significant signs for phenotyping were identified: age of asthma onset, proven allergy, Phadiatop ImmunoCAP level and blood eosinophils on baseline, concomitant allergic rhinitis, chronic rhinosinusitis with nasal polyps and hyper-sensitivity to NSAIDs. The main signs of allergic severe asthma determined: early onset, proven allergy and a positive result of Phadiatop ImmunoCAP (the probability of allergic phenotype increases with Phadiatop ≥ 1.53 PAU/l). Signs of non-allergic eosinophilic asthma were eosinophilia ≥ 150 cells/µl, absence of allergy, concomitant chronic rhinosinusitis with nasal polyps and hypersensitivity to NSAIDs, late onset (after 30 years). Signs were identified for mixed asthma: presence of proven allergy or latent sensitization in combination with high level of Phadiatop ImmunoCAP, late onset, eosinophilia ≥ 300 cells/µl, chronic rhinosinusitis with nasal polyps, hypersensitivity NSAIDs.Conclusions. The algorithm for severe asthma phenotyping based on the isolation of eosinophilia of allergic and non-allergic origin is proposed. Severe asthma phenotyping, which can be carried out in real clinical practice, should facilitate the selection of an initial targeted drug.

15 January 2024 in The Clinician
Verified
Journal Article
Open access
PDF file
SVS. S. Vedenskaya
S. S. Vedenskaya
OSO. G. Smolenskaya
O. G. Smolenskaya
VGV. G. Grachev
V. G. Grachev
EKE. S. Klyachina
E. S. Klyachina
IKI. N. Kupriyanova
I. N. Kupriyanova
VVV. A. Vedensky
V. A. Vedensky
Aim. To determine the features of hemostasis system disorders and the possibility of their correction in patients with arterial hypertension (AH) and multifocal atherosclerotic lesions (MFA) with risk factors indicated.Materials and methods. The study included 135 patients (mean age 53.7 ± 7.76 years), including 80 patients with controlled AH stage and II (group 1) and 55 patients with controlled AH stage III who had ischemic stroke (group 2). Among all patients studied, 33 patients (24.4 %) were smokers. All 135 patients received comparable antihypertensive, antiplatelettherapy (acetylsalicylic acid at a dose of 100 mg/day), had MFA and target lipid spectrum values.Results. Procoagulant shifts are noted already in patients with AH stage I and II, especially in the presence of smoking. Such indices of global thrombodynamics test as initial clot growth rate, average clot growth rate, clot size significantly exceed the reference values and indicate high prothrombogenic potential in patient with AH and MFA. Prescription of dual antiplatelet therapy allows normalization of identified disorders. Presence of risk factors (smoking) aggravates existing hemostasis disorders in patients with AH and MFA.Conclusion. Smoking cessation, optimization of risk factors and complex antihypertensive, hypolipidemic and antithrombotic therapy are the basis of treatment of patients with AH and MFA and can be considered as priority measures to reduce morbidity and mortality in this patient population.

4 November 2022 in Ural Medical Journal
Verified
Journal Article
Open access
PDF file
EKE. S. Klyachina
E. S. Klyachina
OSO. G. Smolenskaya
O. G. Smolenskaya
AMA. G. Makarochkin
A. G. Makarochkin
SVS. S. Vedenskaya
S. S. Vedenskaya
Introduction. Statins have a large number of pleiotropic effects, due to which they can be effective in cardiovascular complications of COVID-19. The aim of the study was to evaluate the relationship of regular statin intake with death and the development of new cardiovascular events in patients with cardiovascular pathology in the acute period of COVID-19. Materials and methods. A retrospective cohort study of patients diagnosed with COVID-19 with a history (before COVID-19) of cardiovascular pathologies, in which regular intake of lipid-lowering drugs is indicated, was conducted. Results. The study included 131 patients: 54 (41,22 %) people with a fatal outcome in the hospital; 77 (58,78 %) patients discharged from the infectious diseases hospital. During the period of hospitalization, 9 (16,67 %) cardiovascular events were documented in patients with a fatal outcome, more often in patients not taking statins, p = 0,399. The chance of death among hospitalized patients with COVID-19 with concomitant cardiovascular pathology is 2,62 times lower in patients taking statins, compared with patients who do not use these drugs for the treatment of cardiovascular diseases (OR 0,381; 95 % CI: 0,17–0,84), the differences are statistically significant (p = 0,015). Discussion. The beneficial effect of long-term statin intake observed in the acute period of COVID-19 is probably due to their additional protective effects: anti-inflammatory, antithrombotic, immunomodulatory and reducing endothelial dysfunction. Conclusions. Among patients with cardiovascular diseases hospitalized for COVID-19, only 1/3 takes the necessary lipid-lowering therapy. The use of statins before admission to the hospital and during treatment significantly reduces deaths in patients with cardiovascular pathology.

4 March 2022 in Clinical Medicine (Russian Journal)
Verified
Journal Article
Closed access
PDF file
EKE. S. Klyachina
E. S. Klyachina
OSO. G. Smolenskaya
O. G. Smolenskaya
During the pandemic caused by the SARS-CoV-2 virus, patients with cardiovascular diseases (CVD), which are often found in the population, are a special risk group. Cardiovascular complications after COVID-19 can occur at diff erent periods of the disease. This research describes cardiovascular complications in patients after recovery.The aim of the study was to identify the incidence of new CVD and complications of existing cardiac pathology in patients who recovered from COVID-19.Material and methods. A retrospective, observational study including 370 patients was conducted. All patients underwent telephone consultations within 6 months after the infectious diseases hospital discharge. When new CVDs, complications or anabasis were identifi ed, follow-up visits were initiated.Results. Among 370 patients under the study, concomitant CVD was registered in 249 (67.29%) people, 121 (32.71%) patients had no case history of cardiovascular pathology. In patients with concomitant CVD during the fi rst 6 months after the infectious diseases hospital discharge, 25 (10.04%) new cardiovascular events were registered, which is signifi cantly more frequent than in patients without case history of CVD (n = 1; 0.83%). The number of events described above was more often observed in the fi rst 3 months after discharge, which is statistically signifi cant (p ˂ 0.05). BP destabilization was most often observed (n = 67; 27.2%) as anabasis, which may be associated with an increased level of anxiety in patients. It was also noted that new CVDs, as well as anabasis, developed because of the timely specialized cardiological medical care absence, which probably led to undesirable events due to inability to correct CVD risk factors in time.Conclusions. In patients with concomitant CVD, who have had COVID-19, in contrast to patients without case history of CVD, the risk of developing new cardiovascular events is signifi cantly higher. Patients with CVD deserve the closest attention during the fi rst 3 months after discharge from the infectious diseases hospital.

23 March 2026 in USMU Medical Bulletin
Verified
Journal Article
Open access
PDF file
EKEkaterina S. Klyachina
Ekaterina S. Klyachina
OSOlga G. Smolenskaya
Olga G. Smolenskaya
SVSvetlana S. Vedenskaya
Svetlana S. Vedenskaya
Introduction. Recently cardiac diseases depression, and anxiety have shown high levels of comorbidity. Over the past 5 years, the COVID-19 pandemic has also made an important contribution to the development of anxiety and depression, which has had a significant impact on the prognosis and quality of life of patients. The aim of the study is to evaluate the indicators of anxiety and depression in patients with hypertension who have had pneumonia caused by COVID-19 who do not reach the target blood pressure values, as well as to study the effect of psychopharmacotherapy in this category of patients during 3 months of follow-up. Methods. A prospective study of patients with COVID-19 who had uncontrolled hypertension and increased anxiety/depression was conducted. Patients from 2 groups were compared: group 1 — patients who took only antihypertensive therapy (n = 23), group 2 — patients who used psychopharmacotherapy in addition to antihypertensive therapy (n = 21). Results. Reactive anxiety was registered in all patients from 2 groups. After 3 months, there was a statistically significant decrease in the high level of reactive anxiety in patients using psychopharmacotherapy. There were no significant changes in the results of reactive anxiety in patients from the comparison group. Depression was detected less frequently than anxiety disorders: group 1 — 3/23 (13,04 %) people (only mild); group 2 — 6/21 (28,57 %) patients (mild — 4/21 (19,05 %); severe — 2 (9,52 %)), p = 0,203. Antidepressants were prescribed only 2 patients with a pronounced level of depression at the initial examination. By the 3rd month of using these drugs, the patients’ depression levels had decreased to moderate. By the 3rd month of follow-up, 8/23 (34,78%) patients in group 1 and 18/21 (85,71 %) patients in group 2 reached the target BP figures, p < 0,001. Conclusion. Patients with increased anxiety and depression who have uncontrolled hypertension should add psychopharmacotherapy to the main antihypertensive therapy in order to stabilize blood pressure and reduce the level of psychoemotional stress.

11 July 2024 in Ural Medical Journal
Verified
Journal Article
Open access
PDF file
SVS. S. Vedenskaya
S. S. Vedenskaya
OSO. G. Smolenskaya
O. G. Smolenskaya
VGV. G. Grachev
V. G. Grachev
EKE. S. Klyachina
E. S. Klyachina
KSK. V. Shirobokova
K. V. Shirobokova
The aim of the work to determine the features of hemostasis and blood rheology in patients with arterial hypertension (HTN) and multifocal atherosclerosis (MFA).Materials and methods. The study enrolled male and female patients aged from 40 to 70 years, including 59 patients with controlled stage I–II hypertension and multifocal vascular lesions (Group 1) and 42 patients with controlled stage III hypertension, who have suffered an ischemic stroke and have multifocal vascular lesions (Group 2). A test using the Thrombodynamics analyser system T-2 (GemaKor, LLC, Moscow, Russia) was performed to detect the impairment of hemostasis.Results. Patients with HTN and MFA have an impaired coagulation hemostasis system (an increase in the initial and stationary clot growth rate and the size of the clot, as well as the presence of spontaneous clots), which leads to a high residual risk of cerebral complications, despite BP lowering to target figures and control of lipid profile.Discussion. Elevated blood pressure in patients with MFA leads to endothelial dysfunction, which is accompanied by activation of coagulation and fibrinolysis pathways. These changes lead to a violation of microcirculatory hemostasis in the brain, the development and progression of cerebral ischemia, and subsequently the occurrence of stroke, both the first and repeated.Conclusion. An important result of this study is the first registered change in the coagulation link of hemostasis in patients with HTN and MFA aged from 40 to 70 years, which can be considered an additional criterion for stroke prediction.